Oncology Information System Market By Product/System Type (Radiation Oncology Information Systems, Medical Oncology Information Systems, Surgical Oncology Information Systems, Oncology Clinical Trial Management Systems, Electronic Patient-Reported Outcome Systems, Cancer Registry and Surveillance Systems); By Application (Treatment Planning and Management, Patient Scheduling and Workflow Management, Clinical Documentation, Chemotherapy and Drug Management, Radiation Record-and-Verify, Patient Engagement and Symptom Monitoring, Clinical Trial Management, Cancer Registry and Reporting, Analytics and Outcomes Management); By End User (Hospitals, Comprehensive Cancer Centers, Radiation Oncology Centers, Medical Oncology Clinics, Ambulatory Cancer Care Centers, Academic and Research Institutes, Public Cancer Registries); By Deployment Mode (On-Premise, Cloud-Based, Hybrid); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Oncology Information System Market: Treatment Workflow Integration and Recurring Software Revenue Shape Market Growth

The Global Oncology Information System Market to grow from USD 3.6 billion in 2025 to USD 6.4 billion by 2032 at a 8.5% CAGR, according to Strategic Market Research.

 

Oncology information systems coordinate cancer-care records across radiation therapy, systemic treatment, surgery, imaging, pathology, laboratory services, pharmacy, scheduling, billing, and follow-up. Revenue comes from enterprise licenses, SaaS subscriptions, implementation, interfaces, data migration, training, upgrades, and technical support.

 

Software is internally estimated to account for 66.0% of 2025 revenue, equivalent to approximately USD 3.82 billion, while implementation, integration, maintenance, training, and other services represent the remaining 34.0%, or about USD 1.97 billion. Software revenue is projected to grow at an 8.8% CAGR to nearly USD 6.90 billion by 2032, while services are expected to expand at approximately 9.9% annually to about USD 3.80 billion as hospitals add interfaces, migrate legacy records, and extend platforms across additional care sites.

 

Radiation oncology has the strongest dependence on specialized software because approved treatment data must move accurately from planning systems into record-and-verify and delivery workflows. Medical oncology adds repeated drug-cycle management, infusion scheduling, laboratory monitoring, and toxicity documentation. Surgical oncology, clinical research, patient-reported outcomes, and cancer registries extend the software environment beyond treatment delivery.

 

Cancer Caseloads Increase the Volume and Duration of Oncology Records

WHO estimated approximately 20.6 million new cancer cases worldwide in 2024 and projects annual diagnoses to reach about 35 million by 2050. Rising incidence increases the number of pathology reports, imaging studies, staging records, treatment plans, prescriptions, adverse-event assessments, and follow-up records handled by cancer services. Hospitals and oncology networks purchase the software, so patient growth raises system workload more rapidly than the number of installations. 

Cancer records may remain active through diagnosis, systemic therapy, radiation, surgery, surveillance, recurrence, and survivorship. General hospital records can store separate encounters, while oncology platforms organize the sequence of treatment decisions and clinical activity across specialties.

Software requirements expand with the number of clinical users, care locations, treatment machines, interfaces, and modules covered by each deployment. A health system may operate several cancer centers under one enterprise agreement, creating greater integration and support requirements than a group of independent practices using smaller installations.

 

Different Oncology Services Require Different Information Systems

Radiation Oncology OIS and Record-and-Verify Systems

Radiation oncology uses highly specialized clinical information systems. Radiation EMRs and treatment-management platforms coordinate simulation, prescriptions, treatment plans, image review, fraction scheduling, quality assurance, dose records, and delivery-machine activity.

Record-and-verify systems compare approved treatment parameters with information received by the delivery equipment and retain a record of every delivered fraction. Siemens Healthineers describes its radiation OIS as supporting scheduling, treatment-response documentation, billing, treatment plans, images, and delivered-dose histories. 

Radiation oncology information systems are internally estimated to represent 43.2% of the market in 2025, equivalent to approximately USD 2.50 billion. Revenue from this application is projected to grow at an 8.7% CAGR and reach about USD 4.49 billion by 2032. The segment retains the largest share because treatment delivery depends directly on machine connectivity, verified prescriptions, fraction records, image access, and long-term dose documentation.

The IAEA’s DIRAC database covers more than 8,500 radiotherapy centers and over 20,000 treatment units across more than 150 countries. Treatment sites require patient identification, scheduling, equipment connectivity, workflow control, and long-term record retention, making radiotherapy infrastructure a practical indicator of radiation-focused OIS deployment potential. 

More than one million Americans receive radiation treatment annually. Those patients generate repeated scheduling, chart-review, image-management, dose-documentation, billing, and quality-control activity throughout their treatment courses. Software revenue remains linked to facility installations, modules, interfaces, and service agreements rather than individual radiation sessions. 

 

Medical Oncology Clinical Information Systems

Medical oncology systems manage regimen selection, treatment-cycle schedules, laboratory thresholds, chemotherapy and immunotherapy orders, pharmacy communication, dose changes, toxicities, and response assessments. Infusion, laboratory, pharmacy, and financial information must remain synchronized throughout repeated treatment episodes.

Medical oncology clinical information systems are estimated to account for 28.7% of 2025 revenue, or approximately USD 1.66 billion. The segment is projected to grow at a 9.6% CAGR to nearly USD 3.16 billion by 2032 as cancer centers adopt structured regimen management, pharmacy integration, treatment-cycle monitoring, and patient-reported outcome tools.

CMS’s Enhancing Oncology Model includes 28 physician group practices, more than 2,000 practitioners, and over 350 sites of care. Participating practices accept accountability for quality and spending during six-month systemic-treatment episodes and maintain care plans, navigation services, electronic patient-reported outcomes, and certified electronic records. Structured medical-oncology data supports episode monitoring, quality reporting, and service coordination, although the software itself is not separately reimbursed. 

Medical oncology platforms also require more detailed drug-management functions than radiation systems. ARIA’s medical oncology configuration includes chemotherapy and drug ordering, pharmacy support, clinical decision tools, trial functions, charge capture, data analysis, and reporting. 

 

Surgical Oncology Documentation Modules

Surgical oncology modules organize tumor-board decisions, preoperative planning, surgical staging, pathology reconciliation, procedure documentation, and longitudinal follow-up. Hospitals often deploy these functions within a broader EHR or multimodality oncology platform rather than purchasing a separate surgical system.

Surgical oncology documentation systems are internally estimated to contribute 9.8% of market revenue in 2025, equivalent to approximately USD 570 million. Revenue is projected to increase at an 8.2% CAGR to nearly USD 990 million by 2032. Growth remains slower than in medical oncology and patient-reported outcome systems because surgical functions are frequently included within broader hospital EHR or enterprise oncology contracts.

Siemens Healthineers describes ARIA as combining radiation, medical, and surgical oncology information within an oncology-specific electronic record. RayCare also supports multidisciplinary oncology workflows, although RaySearch reported in 2025 that further development of surgical-oncology functions remained part of its product roadmap. 

Public sources do not report a separate installed base for surgical oncology modules. Hospital cancer-program activity provides a more useful indication of the related data workload. The National Cancer Database receives information from more than 1,500 accredited programs, contains approximately 40 million records, and covers nearly 74% of U.S. cancer diagnoses. Participating programs must capture and validate surgical staging, pathology, treatment, and outcome information. 

 

Oncology Clinical Trial Management Systems

Clinical trial management systems handle site activation, patient eligibility, protocol calendars, consent status, adverse events, investigational products, monitoring, and regulatory documentation. Cancer centers running several studies use dedicated platforms to connect research activity with routine care and reduce duplicate data entry.

Oncology CTMS platforms are estimated to represent 7.4% of 2025 revenue, or approximately USD 430 million. The segment is projected to grow at a 10.4% CAGR and reach about USD 860 million by 2032 as cancer centers manage more decentralized, biomarker-selected, and multicenter studies requiring standardized enrollment, protocol, and safety records.

The National Cancer Institute’s National Clinical Trials Network coordinates cancer trials at more than 2,200 sites in the United States, Canada, and other countries. The network requires standardized enrollment, protocol, regulatory, biospecimen, and follow-up information across participating institutions.

Academic cancer centers, research hospitals, contract research organizations, and large community networks account for most dedicated CTMS use because their trial volumes justify specialized infrastructure. NCI also operates central services for regulatory-document processing, site registration, and patient enrollment across supported multicenter studies. 

 

Electronic Patient-Reported Outcome Systems

Electronic patient-reported outcome systems collect symptoms, pain, functional status, and treatment toxicities between appointments. Integrated applications can route severe responses to oncology teams and display patient reports alongside laboratory results, medications, and treatment records.

Electronic patient-reported outcome systems are internally estimated to account for 5.2% of 2025 revenue, equivalent to approximately USD 300 million. The segment is projected to record the fastest application-level growth, expanding at a 12.1% CAGR to nearly USD 670 million by 2032 as value-based oncology programs and remote symptom-monitoring initiatives move patient reporting into routine care.

CMS requires Enhancing Oncology Model participants to collect and monitor ePRO data. The model covers more than 350 sites and over 2,000 practitioners, providing a defined implementation environment for electronic symptom monitoring in value-based medical oncology. 

Patient-reporting applications are more useful when clinical teams can review and act on responses within the main oncology workflow. Separate portals can create additional inboxes and duplicate monitoring work, while integrated modules support triage, navigation, symptom escalation, and quality reporting within the existing patient record.

 

Cancer Registry and Surveillance Software

Cancer registry systems collect diagnosis, tumor characteristics, staging, initial treatment, survival, and outcome data for institutional quality programs and public-health surveillance. CDC’s Registry Plus suite supports data collection, tumor linkage, record consolidation, validation, and central registry processing. 

Cancer registry and surveillance systems are estimated to represent 5.7% of the market in 2025, equivalent to approximately USD 330 million. Revenue is projected to grow at a 7.8% CAGR and reach nearly USD 560 million by 2032. Publicly funded registry platforms limit commercial license revenue, but hospitals and agencies continue to spend on interfaces, electronic pathology reporting, validation, cloud processing, and data modernization.

More than 1,500 accredited U.S. cancer programs contribute information to the National Cancer Database, which contains around 40 million records. Registry obligations require hospitals to maintain interfaces, extract structured fields, validate staging information, and correct incomplete or inconsistent records. 

Public-health registry software may be distributed without a commercial license, but hospitals and public agencies still spend on interfaces, cancer registrars, data validation, technical maintenance, and reporting support. CDC initiatives involving cloud processing, electronic pathology reporting, and natural-language processing are reducing dependence on manual abstraction. 

 

Fragmented Clinical Systems Increase Interface and Migration Work

Cancer centers commonly operate separate EHRs, PACS platforms, laboratory systems, pharmacy applications, billing software, treatment-planning systems, and delivery machines. Oncology platforms must exchange information with each system while preserving clinical meaning, user permissions, and historical treatment records.

Implementation work includes data mapping, configuration, interface testing, migration, validation, and staff training. Multisite networks require more extensive integration because acquired hospitals may use different software versions, equipment suppliers, and documentation practices.

Services linked to implementation, integration, migration, training, maintenance, and technical support are estimated to represent USD 1.97 billion, or 34.0% of the market, in 2025. The segment is projected to grow at approximately 9.9% annually and reach about USD 3.80 billion by 2032 as enterprise installations become more complex and hospitals add interfaces without replacing the complete platform.

Provider assessments have identified weak integration, excessive clicks, limited customization, and difficulty connecting medical oncology applications with broader hospital systems. Local software configurations and different product versions can prevent clinical information from moving consistently between departments. 

ARIA supports HL7 and DICOM connectivity across hospital systems and treatment equipment. RayCare v2025 added stronger hospital interoperability, automated staging, improved patient-record management, and workflow automation. RayCare also connects with delivery systems from multiple manufacturers, allowing cancer centers to operate mixed equipment environments without relying entirely on one supplier. 

 

SaaS Shifts More Software Spending Into Recurring Contracts

Elekta reported that 23% of its OIS software orders were SaaS in fiscal 2025/26. The figure confirms that subscription delivery has become a material part of oncology software ordering within a major supplier’s portfolio, although it does not represent a global cloud-adoption rate.

On-premise deployment is internally estimated to account for 57.8% of market revenue in 2025, equivalent to approximately USD 3.35 billion. The segment is projected to grow at a 7.2% CAGR and reach about USD 5.44 billion by 2032 as hospitals retain locally hosted environments for treatment-critical functions.

Cloud-based and SaaS platforms are estimated to hold a 29.4% share, or approximately USD 1.70 billion, in 2025. Revenue is projected to expand at a 12.1% CAGR to about USD 3.79 billion by 2032, making cloud deployment the fastest-growing delivery model. Hybrid systems represent the remaining 12.8%, or approximately USD 740 million, and are projected to grow at a 10.3% CAGR to nearly USD 1.47 billion.

SaaS converts part of the initial license expenditure into recurring payments and allows software providers to centralize upgrades, remote support, and selected security functions. Multisite networks can maintain common software versions across facilities, reducing local configuration differences and simplifying network-wide reporting.

Cloud deployment still requires migration, interfaces, user configuration, access controls, recovery planning, and service-level commitments. Treatment systems may continue to operate locally while analytics, patient engagement, or selected workflow applications move to hosted infrastructure.

 

Maintenance and Upgrades Extend Revenue Beyond Installation

Oncology information systems remain embedded in daily clinical operations for years after implementation. New treatment machines, additional sites, cybersecurity patches, reporting changes, and software releases create recurring service work without requiring full platform replacement.

Elekta earns revenue through initial system sales and recurring maintenance, support, licenses, and upgrades. The company identifies lifecycle management of installed systems as an important part of its operating model. 

RaySearch generated SEK 524.4 million in support revenue during 2025, up 11% and equal to 39% of company sales. Its support backlog reached SEK 1.158 billion at year-end. The figures include software beyond RayCare, but they demonstrate the scale of recurring maintenance and upgrade revenue within oncology software portfolios. 

RayCare was installed in 31 clinics across 13 countries by the end of 2025. Its installed base remains limited compared with global radiotherapy infrastructure, but each reference site strengthens the platform’s clinical track record and provides experience in migration, integration, and multivendor deployment.

 

Workflow Automation Must Reduce Repetitive Clinical Work

Cancer centers are managing larger record volumes without proportional growth in oncologists, physicists, dosimetrists, nurses, and administrative staff. Automation has practical value when it assigns tasks, removes duplicate entry, identifies incomplete treatment steps, or shortens preparation time.

RayCare v2025 introduced automated cancer staging and expanded workflow automation. Elekta positions MOSAIQ as the information backbone of Elekta ONE, while Siemens Healthineers is extending ARIA CORE across systemic therapy, patient engagement, analytics, and multimodality oncology workflows. 

A U.S. study of 318 ambulatory health systems found that copy-and-paste accounted for 38% of oncology note composition, compared with 23% among other physicians. Oncology-specific templates, protocol-linked documentation, and structured toxicity records can reduce repetitive work, while poorly configured alerts risk adding another administrative burden. 

 

Reporting Standards Require Accurate and Structured Oncology Data

NHS England’s costing guidance requires radiotherapy clinical information-system outputs to reflect agreed clinical and Healthcare Resource Group codes. Radiotherapy information also contributes to patient-level costing and the national Radiotherapy Dataset. Missing or incorrectly mapped treatment events can affect reconciliation, reporting, and financial administration.

Registry accreditation and value-based oncology programs create similar data requirements in the United States. Cancer programs submit structured staging and treatment information, while Enhancing Oncology Model participants report clinical, quality, and sociodemographic data.

Country-specific coding and dataset requirements add configuration and maintenance work. Software providers must update interfaces, revise local reporting formats, and retrain users when standards or reimbursement rules change.

 

Cancer Network Consolidation Expands Cross-Site Data Coordination

Comprehensive cancer centers manage radiation therapy, systemic treatment, surgery, imaging, pathology, pharmacy, research, and survivorship across one care pathway. Multisite networks must keep treatment histories, clinical protocols, and scheduling practices consistent across hospitals and satellite facilities.

Hospitals and comprehensive cancer centers are internally estimated to account for 48.6% of market revenue in 2025, equivalent to approximately USD 2.81 billion. The segment is projected to grow at a 9.4% CAGR and reach nearly USD 5.28 billion by 2032. Radiation oncology centers represent approximately 19.7%, or USD 1.14 billion, while medical oncology and infusion clinics account for about 14.8%, or USD 860 million.

A 2026 U.S. study reported that 68.5% of counties, representing 50.8 million people, had no radiation oncology site in 2025. Another 427 counties lost radiation oncology locations between 2018 and 2025. Rural sites had 44% higher odds of disappearing than urban facilities, while freestanding locations had 56% higher odds of closing than hospital-affiliated sites. (ASTRO)

Loss of local facilities can move treatment activity toward regional cancer centers and hub-and-spoke networks. Larger networks require shared records, referral tracking, remote review, and cross-site worklists. Consolidation may reduce the number of independent installations while increasing the number of patients, machines, and locations managed through each enterprise platform.

 

Radiotherapy Modernization Opens Integration and Upgrade Opportunities

UK committed £70 million to new radiotherapy equipment across 28 hospitals. The program is expected to protect up to 13,000 appointments from equipment breakdown and support as many as 27,500 additional treatments annually by March 2027. New machines require connectivity, commissioning, workflow testing, and staff training even when the original funding does not identify a separate OIS budget. 

Uzbekistan plans to introduce a National Cancer Control Program from 2027, replace outdated cobalt units with linear accelerators, and expand brachytherapy and multidisciplinary care. The country also plans an electronic system for palliative-care registration, referral, and support. Scheduling, treatment records, referral management, and equipment interfaces will become more important as treatment capacity expands.

North America is internally estimated to hold 41.5% of global revenue in 2025, equivalent to approximately USD 2.40 billion, and is projected to grow at an 8.2% CAGR to nearly USD 4.17 billion by 2032. Europe represents an estimated 28.1%, or USD 1.63 billion, and is projected to grow at an 8.5% CAGR to about USD 2.88 billion.

Asia-Pacific accounts for an estimated 22.6% share, equivalent to approximately USD 1.31 billion in 2025, and is projected to expand at an 11.4% CAGR to nearly USD 2.75 billion by 2032. Treatment-capacity additions, digital hospital investment, and specialist cancer-center expansion make Asia-Pacific the fastest-growing regional market. Latin America and the Middle East and Africa together represent approximately 7.8% of 2025 revenue, with adoption concentrated in larger urban hospitals and public cancer programs.

Lower-resource countries require radiotherapy equipment, trained staff, reliable connectivity, and capital funding before cancer burden can translate into substantial OIS adoption. Hosted systems and phased public projects may reduce initial infrastructure requirements, but software deployment will continue to follow treatment capacity.

 

Integrated Equipment Portfolios Compete With Specialist Software Platforms

Siemens Healthineers/Varian and Elekta combine oncology information systems with treatment planning, radiation delivery, and long-term service. Their equipment relationships allow software upgrades to be included in machine-replacement and digital-oncology projects. 

RaySearch competes through specialist oncology software, modular architecture, automation, and multivendor connectivity. Its first RayCare order in China was announced in April 2026 for the Shanghai Proton and Heavy Ion Center, extending the platform into an advanced particle-therapy facility. 

General EHR vendors rely on hospital-wide deployments and integrated patient records. Specialist OIS suppliers rely on oncology-specific workflows, treatment-device connectivity, and deeper clinical functions.

No complete public dataset reports current vendor shares or country-level OIS installations. Equipment footprints, disclosed orders, product breadth, and support revenue indicate competitive reach but do not support precise market-share calculations.

 

Market Outlook

Radiation oncology will remain the largest infrastructure-dependent application because treatment delivery requires verified records and machine connectivity. Its internally modeled 43.2% share in 2025 is expected to narrow gradually as medical oncology, CTMS, and ePRO systems grow more quickly.

Medical oncology will expand platform use through regimen management, pharmacy integration, ePRO collection, and episode reporting. Electronic patient-reported outcome systems are projected to record the highest application CAGR at 12.1%, while cloud and SaaS deployment is expected to lead deployment growth at the same 12.1% rate.

SaaS, maintenance, upgrades, and managed services will account for a growing share of supplier revenue through 2032. Existing installations can generate additional sales when cancer centers add locations, treatment machines, clinical users, analytics, patient-engagement tools, or cybersecurity services.

Cancer networks will retain platforms that maintain reliable treatment workflows and reduce manual coordination between departments. Interoperability, migration performance, oncology-specific functionality, cybersecurity, and long-term service will determine which suppliers remain embedded in clinical operations.
 

Oncology Information System Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.6 Billion
Revenue Forecast in 2032	USD 6.4 Billion
Overall Growth Rate	CAGR of 8.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product/System Type, By Application, By End User, By Deployment Mode, By Geography
By Product/System Type	Radiation Oncology Information Systems, Medical Oncology Information Systems, Surgical Oncology Information Systems, Oncology Clinical Trial Management Systems, Electronic Patient-Reported Outcome Systems, Cancer Registry and Surveillance Systems
By Application	Treatment Planning and Management, Patient Scheduling and Workflow Management, Clinical Documentation, Chemotherapy and Drug Management, Radiation Record-and-Verify, Patient Engagement and Symptom Monitoring, Clinical Trial Management, Cancer Registry and Reporting, Analytics and Outcomes Management
By End User	Hospitals, Comprehensive Cancer Centers, Radiation Oncology Centers, Medical Oncology Clinics, Ambulatory Cancer Care Centers, Academic and Research Institutes, Public Cancer Registries
By Deployment Mode	On-Premise, Cloud-Based, Hybrid
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	• Increasing adoption of digital oncology workflows and integrated cancer care platforms • Rising demand for precision oncology, data-driven treatment decisions, and interoperability across healthcare systems • Growing use of cloud-based healthcare IT solutions, AI analytics, and real-time patient monitoring tools
Customization Option	Available upon request